Key facts
- This page summarizes BioXcel Holdings, Inc.'s Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2021, 17:21.
BioXcel Holdings, Inc. - 25 Jun 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BTAI
- Reported as of
- 25 Jun 2021
- Net transaction value
- -$14,589,493
- Reporting owner signature
- /s/ Krishnan Nandabalan,President
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
BioXcel Holdings, Inc. filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 29 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$14,589,493.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
transaction
Common Stock
Sale
- Transaction value
- $14,589,493
- Shares
- -473,250
- Change %
- -5.2%
- Price
- $30.83
- Shares after
- 8,546,750
- Date
- 25 Jun 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.
Footnote F2
These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of the Reporting Person. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.